Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in MS

Neurobiology and immunology:
Interleukin 1beta (IL-1beta) is a major pro-inflammatory cytokine. This study investigated CSF levels of IL-1beta in 170 patients with relapsing remitting MS (RRMS) when the individuals were in both clinical and radiological remission. The individuals were then followed up over four years with clinical, MRI and optical coherence tomography (OCT) measures.

Results showed that detectable levels of IL-1beta in the CSF were associated with a higher progression index, higher Multiple Sclerosis Severity Scale (MSSS) scores and worsening of EDSS scores at follow-up. Patients with undetectable levels of IL-1beta in the CSF had a lower progression index, lower MSSS scores and less retinal nerve fibre layer thickness and macular volume alterations measured using OCT.

These results show that detectable levels of IL-1beta in RRMS patients during clinical and radiological remission seem to be associated with negative prognostic factors.

: Rossi S, Studer V
Source: J Neuroinflammation. 2014 Feb 18;11(1):32. [Epub ahead of print]
Read the abstract


Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial